MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses

MetaVia Inc.

Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.
Part 3A tests one-step titration to 48 mg; Part 3B two-step to 64 mg; primary endpoints safety/tolerability.
Initial dosing expected April 2026; data readout expected Q4 2026.
CEO cites prior 48 mg cohort results: ~9% weight loss, improved glycemic control, favorable safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.